Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of PF-08049820 in adults with moderate to severe atopic dermatitis
CTR20262235Phase 2Active
- Sponsor
- Pfizer
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PF-08049820 in atopic dermatitis (AD), sponsored by Pfizer. Started Aug 2026; status: active.
02
Drugs
PF-08049820
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20262235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262235.